<i>BRCA</i> Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art
In the field of gynecology, the approval of the PARP inhibitors (PARPi) has been changing the treatment of ovarian cancer patients. The <i>BRCA</i> genetic test and the HRD test are being used as a companion diagnosis before starting PARPi treatment. BRACAnalysis CDx<sup>®</sup&...
Main Authors: | Masayuki Sekine, Koji Nishino, Takayuki Enomoto |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2562 |
Similar Items
-
Differences in Ovarian and Other Cancers Risks by Population and <i>BRCA</i> Mutation Location
by: Masayuki Sekine, et al.
Published: (2021-07-01) -
Effect of risk-reducing salpingo-oophorectomy on the quality of life in Korean BRCA mutation carriers
by: Sumin Chae, et al.
Published: (2021-08-01) -
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
by: Nasim Mavaddat, et al.
Published: (2020-01-01) -
Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy
by: Arai, M., et al.
Published: (2022) -
Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO)
by: P. I. Stanciu, et al.
Published: (2019-05-01)